All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
T-cell receptor (TCR)-based adaptive therapy has significant potential to change the current landscape of cancer immunotherapy. Creative Biolabs have created a TCR platform to overcome the difficulties of TCR therapy development. Our scientists are here to help clients rapidly design, synthesize, and manufacture TCR viral particles to shorten the time of the TCR project.
Fig.1 Antigen recognition by TCRs.1
Creative Biolabs offers ready-to-use TCR viral particle products based on a 3rd generation lentiviral packaging system. Our experts have rich experience in lentiviral cloning and expression. We have the most comprehensive TCR viral particle products with a short turnaround time. We have developed a series of proprietary technologies and reagents and a unique manufacturing process to ensure the production of the highest-quality viral particles ready for transduction of many different cell types. The TCR viral particles with high purity, high titer, and superior performance could be used for high-efficiency transduction of target cells and stably integrated expression.
We are pleased to provide you with our novel technology as another tool at your disposal. If you do not find products that meet your requirements then please contact us. We can tailor a service project to your requirements with custom choice(s) of promoter, fusion, tag, and/or selectable marker.
To find out more about our service, please browse TCR Gene Packaging & Delivery Service.
Reference
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION